- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07673120
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses and Multiple Doses of ABBV-313
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-post: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
California
-
Anaheim, California, Forente stater, 92801
- Rekruttering
- CenExel Act- Anaheim Clinical Trials /ID# 285208
-
-
Illinois
-
Grayslake, Illinois, Forente stater, 60030
- Rekruttering
- Acpru /Id# 283495
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- BMI is >= 18.0 to <= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Exclusion Criteria:
- History of any clinically significant sensitivity or allergy to any medication or food.
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
- Participant has prior exposure to ABBV-313 within the past 300 days.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1, Group 1: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 1, Group 2: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 1, Group 3: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 1, Group 4: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 1, Group 5: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 1, Group 6: ABBV-313 or Placebo
Participants will receive a single dose of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 2, Group 7: ABBV-313 or Placebo
Participants will receive multiple doses of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
|
Eksperimentell: Part 2, Group 8: ABBV-313 or Placebo
Participants will receive multiple doses of ABBV-313 or Placebo |
Injection Injection Infusion Infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to Approximately Day 329
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Approximately Day 329
|
|
Maximum Observed Plasma Concentration (Cmax) of ABBV-313
Tidsramme: Up to Approximately Day 329
|
Cmax of ABBV-313. |
Up to Approximately Day 329
|
|
Time to Cmax (Tmax) of ABBV-313
Tidsramme: Up to Approximately Day 329
|
Tmax of ABBV-313. |
Up to Approximately Day 329
|
|
Terminal Phase Elimination Rate Constant (Beta) of ABBV-313
Tidsramme: Up to Approximately Day 329
|
Beta of ABBV-313. |
Up to Approximately Day 329
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-313
Tidsramme: Up to Approximately Day 329
|
t1/2 of ABBV-313. |
Up to Approximately Day 329
|
|
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-313
Tidsramme: Up to Approximately Day 329
|
AUCt of ABBV-313. |
Up to Approximately Day 329
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: ABBVIE INC., AbbVie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- M26-216
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .